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1. Introduction
Despite the emphasis on arteriovenous fistula creation in patients requiring renal replace‐
ment therapy, catheter-based hemodialysis remains a valuable access option that allows for
immediate initiation. They continue to serve as an important option for chronic kidney dis‐
ease (CKD) patients who are: (a) awaiting a permanent AV access creation or maturation, (b)
in need of acute hemodialysis, (c) have exhausted traditional access routes, and (d) those
suffering from graft infection or extravasation episodes [1].
Catheter-related sheath (CRS) formation, previously referred to as the “fibrin sheath” is a
well documented physiologic reaction occurring between the catheter, vein wall, and blood
elements. The incidence of central venous CRS formation is reported to occur in 42%-100%
of central venous catheters [2-5]. The sheaths can be asymptomatic or result in a number of
complications including withdrawal occlusion, medication extravasation, thrombosis, infec‐
tion and in rare cases pulmonary embolism. Repeat catheter removal and replacement, or
loss of an access route is not infrequently the end result of catheter related sheath formation.
It is important for those clinicians caring for CKD patients to be aware of the clinical and
imaging manifestations of CRS and understand the interventions that can be used to miti‐
gate them.
The goals of this chapter are to review the existing literature on CRS in animals and humans,
to provide a current, coherent explanation of the composition of the CRS and how they
form, and describe the clinical manifestations and treatment options that are available
© 2013 Percarpio et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
2. A brief history of central venous catheters and catheter-related sheaths
formation
The first catheterization of a central vein was performed in 1733 by an English clergyman
named Stephen Hales who fixed a glass tube to the left jugular vein of a mare to measure
venous pressure [6,7]. It wasn’t until the late 1920’s that Werner Forssmann performed the
first documented central venous catheterization in a human when he passed “a well oiled 4F
ureteric catheter” through his left antecubital fossa and into this heart. Remarkably, For‐
ssmann then climbed several flights of stairs to the x-ray department to visualize his cathe‐
ter placement [8,9]. Decades passed and it was not until the 1970’s that the central venous
catheter became widely available [10].
One of the earliest descriptions of CRS covering a central venous catheter described a “fibrin
sleeve” published in the French literature in 1964 by Motin [11]. A number of subsequent
studies referred to the central venous catheter related sheaths as a fibrin sleeve and fibrin
sheath [2,3,5]. More recently, the work of Xiang et al. more accurately described the CRS as
cellular-collagen tissue covered by an endothelial layer. Fibrin was described a component
of an early physiologic response to the catheter that consists of pericatheter thrombus, but
the CRS itself is not composed of fibrin [12]. Subsequent papers by these authors and others
reinforced the concept of CRSs representing a spectrum of thrombosis and thrombus organi‐
zation [13-16].
3. Clinical implications
The most common manifestation of CRS is catheter dysfunction. This interrupts the patient’s
medical therapy, may require intervention ranging from thrombolytic infusion to catheter
removal or exchange, and may have long lasting implications such as loss of specific venous
access locations. Extravasation of fluids or intravenous medication is a less common but cer‐
tainly significant complication that can result in tissue loss and necrosis. Thrombus that
forms on the CRS or the CRS itself can on rare occasion become dislodged and embolize to
the pulmonary circulation. Finally, there have been reports that the presence of the sheath is
a risk factor for catheter-related bacteremia and infection.
When dysfunction is  present,  the patient  is  commonly referred for  radiographic evalua‐
tion of the catheter. A radiograph or fluoroscopy of the chest is performed to document
catheter  tip  position.  Contrast  injection  of  a  normal,  functioning  catheter  should  show
contrast exiting the end-holes and filling a substantial portion of the vein lumen distal to
the  catheter  tip.  When  a  sheath  is  present,  contrast  will  track  in  a  retrograde  fashion
along the catheter. The contrast will then “spill” out into the vein lumen via gaps or fis‐
sures in the sheath.
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Figure 1. Catheter injection under fluoroscopy. The existing catheter has been pulled back approximately 10 cm and
then injected. Contrast fills a well developed sheath considerably narrower than the expected diameter of the superi‐
or vena cava. A guide wire has been advanced through the other catheter lumen and is positioned in the inferior vena
cava in preparation for exchange.
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4. Histopathology of catheter related sheaths
By the middle of the 20th century, central venous catheters were being placed with subclavi‐
an and jugular approaches and used for intravenous infusion [6]. The presence of a tissue-
like covering was reported after catheters had been indwelling for relatively short periods of
time. An early description of this coating appeared in the French literature in 1964 [11].
Since that time, the covering has been referred to as a fibrin sleeve [2,3], a sleeve thrombus
[4], a sleeve [12], and—the most recognized phrase—a fibrin sheath [5]. The reported fre‐
quency of this observation ranges from 42% to 100% [2-5]. Although there are a number of
articles in the literature that are concerned with the clinical aspects of CRS; a minority of
these focus on the sheaths’ histopathologic features and microscopic development.
An often-referenced article [2] describes the findings at autopsy in 55 patients with subclavi‐
an vein catheters. In that study, sheaths were identified in all specimens, even as soon as 24
hours after catheter insertion. Microscopic evaluation was reported to reveal a predominate‐
ly fibrin makeup, “with no evidence of endothelialization or organization.” The sleeve was
observed, in many cases, to be adherent to the adjacent vein wall.
Well into the 1990s, descriptions of a catheter-related sheath consisting of “fibrin and throm‐
bocytes” [17] or a “layer of investing fibrin and proteinaceous material” [18], could still be
found in the literature.
Later, two reports offered a more detailed microscopic and histologic description. In 1996, a
study [19] was performed in which small-caliber silicone catheters were inserted in 15 rats.
The catheters were placed via a jugular approach, and the animals were sacrificed at 3, 7,
and 60 days. Catheter-related thrombus, with points of attachment to the vein wall, was ob‐
served in the earliest group. The thrombus underwent changes typical of organization at the
7-and 60-day observation points and evolved into what was described as a “dense fibrous
connective tissue containing numerous spindle-shaped fibroblasts” [19].
In a second, larger study [12], again performed in a rat model, catheters were placed via the
jugular vein in 123 animals. Histologic changes were studied at catheter indwelling times
that ranged from 1 day to 6 months. A true pericatheter thrombus was identified in all ani‐
mals within the first 3 days after catheter insertion. A transformation occurred from peri‐
catheter thrombus to a more cellular structure composed of collagen with smooth muscle
and endothelial cells; this latter structure appeared 1–4 weeks after catheter placement.
Three kinds of catheter-associated thrombus have been described [14]. The first variety is a
mesh-like thrombus that bridges the vein wall and catheter. This is thought to evolve into the
mixed cellular and collagen catheter-related sleeve described by these authors in an earlier re‐
port [12]. A second, nonorganized form of thrombus has been termed “sleeve-related throm‐
bus” and is found on the distal aspects of the indwelling catheter itself. This variety has no
attachment to the vein wall and is histologically and physically separate. Last, mural throm‐
bus is found on the vein wall adjacent to the distal intravascular aspect of the catheter. This
thrombus undergoes organization and is thought to become incorporated into the vein wall. It
is uncertain why a thrombus at a particular location develops into a cellular bridge instead of
incorporating into a vein wall, although catheter motion may influence this process [20].
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Figure 2. a)Gross photograph of a well developed, circumferential catheter-related sheath (CRS) that formed in a
swine vena cava after only seven days indwelling time. b)Catheter-related sheath from a human autopsy specimen.
The sheath is well developed and there is a prominent pedicle-like attachment to the vein wall. c)Ultrasound (US) im‐
age of a catheter-related sheath (CRS). Transverse US image from the base of a patient’s neck prior to insertion of a
tunneled hemodialysis catheter. There is a rounded structure attached to the anterior jugular vein wall representing
residual CRS. A previous tunneled catheter had recently been removed secondary to infection.
In a large animal model (swine), Forauer et al [16] examined CRS formation at 7, 14, 30, and
45 days after catheter insertion. This confirmed the cellular nature of the sheath including
endothelial and smooth muscle cells; see Figure 3. These cell populations were not randomly
present; the smooth muscle cells assumed a typical orientation to the vessel lumen with the
long axis of the cell oriented with the circumference of the vessel. The smooth muscle cells
were also involved in neovascularity of the sheath, forming small lumens lined with endo‐
thelial cells. The endothelial cells formed a monolayer covering the external portion (vascu‐
lar lumen aspect) of the sheath that was indistinguishable from adjacent vein wall intima.
The development of the catheter-related sheath is postulated to begin with thrombus that
develops after trauma associated with the catheter insertion procedure [3,21]. Local trauma
occurs at the venotomy site. Factors contributing to thrombus formation include disturbance
of normal flow through the venous segment and stasis that occurs between the catheter and
the vein wall. Other locations of trauma occur at foci of friction of the catheter against the
vein wall or catheter tip impact against the vein wall and in segments where catheters lie in
acute angles within the course of the vein [20,21]. In addition, acute or chronic (organized)
thrombus has been confirmed in catheter stripping specimens [13].
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Figure 3. Low-power (x50) micrograph demonstrating smooth muscle cells in the catheter-related sheath. Immuno‐
histochemistry (anti-smooth muscle stain, 1:50) highlights positive staining smooth muscle cells, seen as brown, in
both the vein wall and throughout the sheath (solid arrow). A circular arrangement of smooth muscle cells is present
in the sheath (open arrow), representing neovascularization within the sheath.
The role of catheter-tip trauma and associated thrombus formation has been examined, also in
a swine model [20]. Silicone catheters with or without a 0.018-inch wire stabilizing loop at the
distal indwelling tip were inserted, and their tips were positioned in the distal aspect of the su‐
perior vena cava. In the group in which catheter tips were stabilized by the wire loop, there was
only a mild increase in vein wall thickness without vein wall thrombus. In the control group
(without the stabilizing loop), mural thrombus formed at the site of local vein wall trauma
caused by catheter tip motion. This thrombus subsequently underwent organization and re‐
sulted in vein wall thickening and intimal hyperplasia. The organization of intravascular
thrombus involves an infiltration by smooth muscle cells and the development of a vascular‐
ized connective tissue that includes collagen, smooth muscle cells, and endothelial cells [22,23].
Inflammatory cells are also known to be involved in venous thrombosis [24].
The process of catheter-related sheath formation is a dynamic and ongoing response of the
components of the vein wall to the catheter and associated thrombus. The sequence of the
steps of sheath formation is similar among animals and humans. Inflammatory, endothelial,
and smooth muscle cells are involved in this response, and these are all biologically active
cell types. Findings support the hypothesis that a pathologic process occurs when thrombus
organizes adjacent to a synthetic scaffold—a catheter. This process differs from intravascular
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thrombus formation because the presence of the catheter within the vessel lumen allows the
process to continue with only limited focal vein wall contact.
The role of medical comorbidities, such as diabetes mellitus and hypercholesterolemia, in
the formation of CRS has not been well evaluated. A small randomized study evaluating
the occurrence of late malfunction in tunneled hemodialysis catheters did note a trend to‐
ward late catheter malfunction (either thrombosis or CRS formation) in patients with dia‐
betes,  but this did not reach statistical significance (p=0.054) [25].  Several series focusing
on  peripherally  inserted  central  catheters  and  non-tunneled  internal  jugular  central  ve‐
nous catheters  have shown no clear  relationship between diabetes  or  hypercholesterole‐
mia on thrombotic complications [26-28]. The specific role of hypercholesterolemia in CRS
formation has not been addressed.
5. Clinical manifestations of the CRS
While this process can remain clinically silent, there are many clinically important sequelae
to sheath formation. These include withdrawal occlusion, total occlusion of the catheter [29],
vein thrombosis [4,17,30,31], infusate extravasation [30], pulmonary embolus at catheter re‐
moval [2,4], and predisposition to infection [32-34]. Vessel thrombosis can also result in loss
of the venous access route- a sobering prospect for a patient requiring long-term renal re‐
placement therapy.
The first indication that a CRS is present is often the ability to flush or inject, but the inability to
aspirate from a catheter, termed withdrawal occlusion. This occurs when a CRS encases the tip
of a catheter and effectively forms a one-way valve [35]. Additionally, defects or rents in the
CRS may allow infusion while not providing sufficient area to aspirate; see Figure 1. This per‐
sistent withdrawal occlusion results in chronic catheter dysfunction and poor flow rates. It can
also result in the serious complication of medication extravasation [36]. Medication extravasa‐
tion can result in significant morbidity with administration of chemotherapeutic agents. The
infusate injected into the catheter exits the end-hole, tracks retrograde between catheter and
the sheath and can follow this path back to the venotomy and into the soft tissues; see Figure 4.
The patient may experience pain, inflammation, and tissue necrosis.
The thrombotic complications of pericatheter thrombus formation resulting in a catheter re‐
lated sheath can lead to stenosis or frank occlusion of the veins anywhere along the indwel‐
ling path of the catheter. Intraluminal and mural thrombosis may also contribute to catheter
dysfunction and complete venous thrombosis. The catheter dysfunction secondary to intra‐
luminal thrombosis may also present with persistent withdrawal occlusion secondary to a
“ball–valve” effect within the catheter lumen [37], and may likely manifest resistance to an‐
tegrade flushing as well. Mural thrombi may partially or completely block a vein and are
often asymptomatic, but may present with arm, neck, head or jaw pain, numbness of the ip‐
silateral extremity, erythema, phlebitis or venous distension [37]. In the extreme, the patient
may display symptoms of superior vena cava syndrome.
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Figure 4. Catheter-related sheath causing soft tissue extravasation. a)Early and b) late images from a contrast injec‐
tion of a right sided chest port. No contrast is observed exiting the distal end-hole of the post catheter. The contrast
tracks retrograde along the catheter and exits in the soft tissues of the neck at the level of the venotomy.
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CRS and pericatheter thrombus has also been implicated as a risk factor for infection. Mehall
et al. established that CRS significantly enhanced catheter related infection and bacteremia.
It was postulated that the sheath provides a surface for bacterial attachment and source of
septic emboli [34].
Cases of CRS being dislodged into pulmonary vasculature have been described [4,38]. How‐
ever, this complication appears to be rare or clinically insignificant given the relatively small
volume embolic burden and the bridging of cellular tissue with the vein wall.
6. Clinical interventions and management
6.1. Thrombolytic therapy
An initial, conservative approach to patency restoration is the use of thrombolytic agents.
Thrombolytic therapy for treatment of hemodialysis catheter malfunction due to thrombosis
or CRS has been used for decades. Two basic protocols have been employed: indwelling
(“lock”) catheter treatments and infusion therapies. Indwelling or “lock” treatments involve
administration of a volume of thrombolytic agent which only fills the catheter lumen for a
variable amount of time. Infusion treatments involve the infusion of variable doses of
thrombolytic through the hemodialysis catheter over several hours.
Multiple different thrombolytic medications have been used with the two methods above in
varying doses over the years. Urokinase was the agent of choice for both protocols until its
withdrawal from the North American market in 1999. It was reintroduction to the market in
2002. To date, it is the only thrombolytic agent to be directly compared with percutaneous
catheter related sheath stripping (PCRSS) in a prospective randomized trial. In 2000, Gray et
al found no significant difference in primary patency between urokinase infusion and
PCRSS [39]. Low dose (5000 to 9000 units) indwelling treatments have had mixed results in
the literature with successful return of catheter function ranging from 14% to 95% [40]. More
recently, positive results with high dose urokinase (25,000 to 100000 IU) indwelling treat‐
ments have been reported by Donati et al with recanalization rates up to 100% [41].
Since urokinase was withdrawn from the market in North America, several other thrombo‐
lytic agents have been evaluated. Multiple published reports and a clinical trial have shown
alteplase to be effective and safe [42-45]. There is evidence that alteplase yields similar or
better results compared to UK [46-48]. Although less studied, reteplase has also been shown
to be safe and effective but no direct comparison has been made to the more commonly used
thrombolytic agents [49,50]. Tenecteplase has also been shown in Phase III trials to be safe
and effective in the treatment of dysfunctional catheters [51,52]. Newer thrombolytic agents
such as recombinant-urokinase, afimeprase, and anistreplase are currently under investiga‐
tion [53].
Because the composition of the CRS has a significantly cellular component, the efficacy of
thrombolytics must be attributed to interaction with the associated thrombotic elements that
are present.
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6.2. Percutaneous CRS stripping and other mechanical interventions
Mechanical interventions have also been employed as a treatment for CRSs which result in
occlusion or decreased blood flow rates. Such interventions include catheter exchange and
PCRSS with balloon disruption. Although sheath stripping is used less frequently in favor of
catheter exchange at many institutions, an understanding of the technique is important.
Treatment of occluded central venous catheters by some method of mechanical disruption
has been described in the literature as early as 1983 using a straight guide wire advanced
through the catheter lumen via a Y-valve under simultaneous constant suction with 100%
success [54].
In 1995, Knelson et al [55] described two techniques (a wire only and separate snare techni‐
que) for PCRSS. Eleven of the patents had either a J-tipped wire or tip-deflecting wire ad‐
vanced through the catheter until the curved tip just excited the catheter end, after which it
was rotated several times until contrast injection under fluoroscopy demonstrated patency.
Alternatively, a snare technique was employed via right femoral vein access. Here, a nitinol
loop snare was advanced 5cm over the catheter with the aid of a 6-F guiding catheter, closed
and retracted under moderate tension stripping off the sheath surrounding the catheter.
Nineteen of the twenty treatments were successful with a mean duration of satisfactory
function following intervention of 150 days.
Subsequent retrospective studies have reported high technical success rates [56-59], but with
less promising durable clinical results with 45% and 28% primary patency at 3 and 6 months
respectively [58]. A study specifically evaluating HD catheter flow rates post stripping
yielded more disappointing results: the average flow rate fell below host the institution’s
standard by the fifth hemodialysis session [56]. Suhocki found primary and secondary mean
patency at 3 and 4.5 months respectively [59]. Johnstone found at 6 months primary and sec‐
ondary patency rates of 40% and 60%, respectively [60]. In 1999, Brady et al [61] prospective‐
ly found median post-stripping patency of 89 days(i.e., 3 months).
In 2007, Reddy et al [62] described a new “internal” snare approach as opposed to the “ex‐
ternal” approach from a femoral vein. Here, a nitinol wire was bent in its mid portion 180
degrees resulting in a loop. The loop was then advanced through the proximal lumen until
and then was tightened down on the distal portion of the catheter snaring it. The looped ni‐
tinol wire was also advanced though the distal lumen. Multiple passes were made in each
lumen often resulting in clot/sheath removal. Disruption of the CRS was attributed to two
mechanisms of action: the stripping action of the snare over the distal lumen and the defor‐
mation/expansion of the catheter as the snare is advanced. Nine internal snare procedures
were performed in seven patients who had failed pharmacologic lysis with 100% technical
success. With the internal snare procedure, there was a 100% patency at 8 weeks and a mean
patency of 108.5 days without complication.
In 2002, Angle et al [63] published a five year retrospective analysis of 115 patients with 340
tunneled hemodialysis catheter fluoroscopic evaluations of which underwent one of five in‐
terventions: conservative management (aspiration/flushing), tip-deflecting guide wire ma‐
nipulation, catheter exchange, PCRSS with a snare via femoral approach, and thrombolytic
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infusion. Failure rates at 30 days using the five management strategies above ranged from
24% to 62%. PCRSS had the lowest 30 day failure rate of all the methods evaluated.
There have been two prospective trials comparing the effectiveness of different techniques
on the dysfunctional dialysis catheter. In 2000, Merport et al [64] performed a randomized
prospective clinical trial comparing the effectiveness of over-the-wire catheter exchange ver‐
sus PCRSS over 37 encounters in 30 patients with malfunctioning hemodialysis catheters
which demonstrated 1-month patencies of 93% and 31% respectively. Estimated costs were
lower in the catheter exchange group.
In 2000, Gray et al [39] performed a randomized prospective clinical trial comparing the ef‐
fectiveness of PCRSS with a femoral snare approach versus 250,000 U urokinase infusion
over 4-hours. Forty-five day primary patency rates for PCRSS and urokinase infusion were
35% & 48% respectively and were not statistically significant (p=.2).
6.3. Other alternatives
Hemodialysis catheter exchange with or without CRS balloon disruption with has been well
described with comparable or improved outcomes compared to PCRSS [64-68]. This proce‐
dure is performed by placing guide wires through the existing catheter into the superior or
inferior vena cava, freeing the retention cuff from the surrounding tissues using blunt dis‐
section, and removal of the catheter. Disruption of the CRS can be accomplished by advanc‐
ing a modest diameter (6-8 mm) angioplasty balloon catheter and performing inflations
along the previous course of the catheter; see Figure 5. A new catheter is then advanced over
the guide wires and through the existing subcutaneous tunnel. When performed using strict
sterile technique, there is no increased risk for infection. This strategy has the advantage of
preserving the existing venous access site. The less invasive nature of this procedure is re‐
sponsible for its current widespread application.
Endoluminal brushing of occluded hemodialysis catheters during thrombolysis has been re‐
ported with success [69]. This technique targets only the inner lumen of the catheter, not the
external CRS.
6.4. Catheter material, coatings and shape
A multitude of tunneled hemodialysis catheters have been marketed over the years with dif‐
ferences in catheter material, tip shape, number of side holes and surface coatings with the
hope of reducing complications. While the effects on infection rates and thrombosis of these
different catheter types have been studied, rigorous examination of different catheter types
on CRS formation is less well understood.
Catheter material has traditionally been variants of either silicone or polyurethane. More re‐
cently carbothane has been introduced allowing for greater catheter wall strength and resist‐
ance to certain chemicals. In vivo studies of catheter material with regard to thrombogenicity
and platelet adhesion have had mixed results showing both no difference between polyur‐
ethane and silicone [70] and lower thrombogenicity with polyurethane [71]. Unfortunately,
these studies did not evaluate the relationship between thrombogenicity and CRS formation.
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Figure 5. Balloon disruption of a catheter-related sheath (CRS). a) Inflation of an over the wire angioplasty balloon to
disrupt the sheath.b) Post balloon disruption contrast injection. The full lumen of the superior vena cava is now opaci‐
fied.
A variety of antibiotic and antithrombotic catheter-bound coatings have been developed to
prevent infection and thrombosis. As expected, studies have shown that heparin-coated cen‐
tral venous catheters can reduce central venous catheter thrombotic complications [72,73]. A
retrospective study published in 2009 evaluated the differences in primary patency between
heparin-coated and uncoated hemodialysis catheters. Primary patency at 30 and 90 days
demonstrated a slight trend favoring the heparin-coated catheters, but the results did not
reach statistical significance (p=0.08) [74].
Variations in catheter tip shape, number of lumen and number of side holes continue to evolve
with promises of decreased recirculation, rates of thrombosis and improved flow rates. A
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randomized prospective evaluation of three catheter configurations- paired catheters, split tip
catheters, and stepped lumen catheters was published in 2001. Despite different design and ar‐
rangement of side holes or lumens, all three catheters had similar survival times and flow rates
[75]. In 2008, Kakkos et al attributed differences in tip shape to the significant improvement in
90 day primary assisted patency of the Tal Palindrome Ruby (Covidien; Mansfield, MA, USA))
catheter compared to the HemoSplit (Bard Access Systems; Salt Lake City, UT, USA) tunneled
catheter, 94% versus 71%, respectively [76]. This difference persisted at 180 days.
6.5. Future directions
Considerable effort in current interventional cardiovascular research is focused on drug-
eluting coatings for stents [77]. These coatings consist of cytostatic or cytotoxic agents that
target cell populations involved in stent related restenosis. The characterization of the cellu‐
lar basis of catheter-related sheath formation may initiate further developments in the area
of catheter technologies [78] that could include the development of materials with or with‐
out coatings that prevent, retard, or eliminate the sheath.
7. Summary
Catheter-based hemodialysis remains an important option for many chronic kidney disease
(CKD) patients. In addition to catheter-related infections, CRS formation is responsible for a
significant proportion of catheter dysfunction. It is a dynamic and on-going response of the
vein wall to the catheter and the associated thrombus. It involves biologically active cell
types and there are many similarities with the process of thrombus organization. There have
been numerous methods developed to restore catheter function; thus far, none have provid‐
ed consistent long term, durable results.
Nomenclature
Chronic kidney disease (CKD), catheter-related sheaths (CRS), percutaneous catheter related
sheath stripping (PCRSS)
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